The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 6 for:    Shear Wave | Switzerland

Muscle Ultrasound Study in Shock Patients (MUSiShock)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04550143
Recruitment Status : Recruiting
First Posted : September 16, 2020
Last Update Posted : November 18, 2023
Sponsor:
Information provided by (Responsible Party):
Karim Bendjelid, University Hospital, Geneva

Brief Summary:

Intensive Care Unit (ICU) patients are known to lose muscle mass and function for many reasons, ranging from prolonged immobilization, to the effects of ICU treatments such as mechanical ventilation (MV), to the critical illness itself. Ultrasonography (US) is widely used in the ICU setting and has greatly evolved in the last decades, since it allows the non-invasive assessment of different structures, using radiation-free and user-friendly technology; its application for the assessment or the skeletal muscle is a promising tool and might help detecting muscle changes and thus several dysfunctions during early stages of ICU stay.

By using skeletal muscle ultrasound at both diaphragm and peripheral levels, the overall aim of this study is to improve knowledge in the early detection of muscle dysfunction and weakness , and their relationship with mechanical ventilation weaning and muscle strength, in critically ill patients suffering from septic shock.


Condition or disease Intervention/treatment
Septic Shock Other: Diaphragm ultrasound (DUS) Other: Peripheral Muscle Ultrasound (PMUS) Other: Airway occlusion pressure (P0.1) Other: Medical Research Council (MRC) sum score

Layout table for study information
Study Type : Observational
Estimated Enrollment : 84 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diaphragm Dysfunction and Peripheral Muscle Wasting in Septic Shock Patients: Exploring Their Relationship Over Time Using Ultrasound Technology
Actual Study Start Date : October 13, 2020
Estimated Primary Completion Date : August 2024
Estimated Study Completion Date : August 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Group/Cohort Intervention/treatment
Septic Shock Other: Diaphragm ultrasound (DUS)

DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.

A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = "thickness at end inspiration" - "thickness at end-expiration" / "thickness at end-expiration", %).

SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa).

Other Name: Diaphragm ultrasonography

Other: Peripheral Muscle Ultrasound (PMUS)

PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.

Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:

(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.

CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.

For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.

All assessments will be performed with minimal compression and a copious amount of water-gel.

Other Name: Muscle ultrasonography

Other: Airway occlusion pressure (P0.1)

P0.1 is "the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration". Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.

For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen.


Other: Medical Research Council (MRC) sum score

This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, "no visible/palpable contraction"; 1, "visible/palpable contraction without movement of the limb"; 2, "movement of the limb, but not against gravity"; 3, "movement against gravity"; 4, "movement against gravity and some resistance"; 5, "normal".

The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score <48 indicating the presence of weakness.

Other Name: MRC muscle strength score




Primary Outcome Measures :
  1. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Baseline (at 24 hours after ICU admission) ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  2. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Day 2, after ICU admission ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  3. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Day 3, after ICU admission ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  4. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Day 4, after ICU admission ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  5. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Day 5, after ICU admission ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  6. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Extubation day, approximately 7 days ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  7. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: Weekly (1x/week), counting from day 6 of ICU stay until ICU discharge (approximately 10 days) ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  8. Association between SWE assessment and other muscle ultrasound markers. [ Time Frame: ICU discharge, approximately 10 days ]
    To explore the existence of an association between SWE assessment and other muscle ultrasound markers (TDI, TFDI, CSARF and ECHORF) for each muscle (diaphragm and quadriceps rectus femoris muscles) over the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.


Secondary Outcome Measures :
  1. Association between the rate change (%) in DUS and PMUS assessments. [ Time Frame: Time-points of assessment relating to baseline (ICU admission) values. ]
    The association between the rate change (%) in DUS (TDI, TFDI and SMDI) and PMUS (CSARF, ECHORF and SMRF) markers over time, during the ICU stay, in adult patients (> 18 years old) admitted for a septic shock.

  2. Weaning success/failure predictive model. [ Time Frame: Between ICU admission and extubation moment. ]
    The analysis of a combined model comprising, among other ICU variables, one DUS marker (TDI, TFDI and SMDI) and one PMUS marker (CSARF, ECHORF and SMRF) to predict weaning success/failure, in adult patients (> 18 years old) admitted to the ICU for a septic shock.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This research project will include any adult patient (> 18 years old) admitted to the ICU (University Hospitals of Geneva, HUG) with a diagnosis of septic shock, respecting the pre-defined inclusion and exclusion criteria. No restrictions will be applied to the source of infection.
Criteria

Inclusion Criteria:

  1. adult patients (> 18 years old) admitted to the ICU
  2. with a diagnosis of septic shock
  3. a SOFA score equal or superior to 8 points, at ICU admission
  4. blood lactate concentration above 2 mmol/L, at ICU admission
  5. expected to have more than 48h of mechanical ventilation (estimated by the attending physician)
  6. expected to stay more than 5 days in the unit (estimated by the attending physician)
  7. able to walk prior to ICU admission / walking aids accepted;

Exclusion Criteria:

  1. pregnancy
  2. lower limb amputation, fixators or open wounds
  3. thoracic fixators or open wounds
  4. diagnosed neuromuscular or central nervous system diseases
  5. being transferred from another ICU
  6. spinal cord injury
  7. diaphragm pacemaker
  8. palliative goals of care
  9. cancers derived sarcopenia
  10. cachexia
  11. anorexic disorders (protein-energy malnutrition)
  12. intellectual or cognitive impairments, limiting the ability to follow instructions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04550143


Contacts
Layout table for location contacts
Contact: Karim Bendjelid, MD, PhD +41 22 382 74 46 karim.bendjelid@hcuge.ch
Contact: Ivo Neto Silva, PT, MSc ivo.neto@hcuge.ch

Locations
Layout table for location information
Switzerland
Service de Soins Intensifs, Hôpitaux Universitaires de Genève (HUG) Recruiting
Geneva, Switzerland, 1205
Contact: Ivo NETO SILVA, PT, MSc       ivo.neto@hcuge.ch   
Contact: Karim BENDJELID, MD, PhD       karim.bendjelid@hcuge.ch   
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Layout table for investigator information
Principal Investigator: Karim Bendjelid, MD, PhD Hôpitaux Universitaires de Genève (HUG) / Université de Genève (UNIGE)
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Karim Bendjelid, Professor, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT04550143    
Other Study ID Numbers: 2020-00452
First Posted: September 16, 2020    Key Record Dates
Last Update Posted: November 18, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Karim Bendjelid, University Hospital, Geneva:
Muscle ultrasound
Intensive care unit-acquired weakness
Diaphragm dysfunction
Mechanical ventilation
Weaning
Sepsis
Critical illness
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Shock
Pathologic Processes
Sepsis
Infections
Systemic Inflammatory Response Syndrome
Inflammation